Van ECK Associates Corp Cuts Position in Haleon PLC Sponsored ADR $HLN

Van ECK Associates Corp decreased its position in shares of Haleon PLC Sponsored ADR (NYSE:HLN) by 11.4% during the third quarter, HoldingsChannel reports. The firm owned 2,490,410 shares of the company’s stock after selling 319,765 shares during the period. Van ECK Associates Corp’s holdings in Haleon were worth $22,339,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. SOA Wealth Advisors LLC. lifted its position in Haleon by 60.5% in the third quarter. SOA Wealth Advisors LLC. now owns 3,105 shares of the company’s stock valued at $28,000 after purchasing an additional 1,170 shares during the last quarter. Citizens National Bank Trust Department increased its stake in shares of Haleon by 167.4% in the third quarter. Citizens National Bank Trust Department now owns 3,276 shares of the company’s stock worth $29,000 after buying an additional 2,051 shares during the period. Atlantic Union Bankshares Corp increased its stake in shares of Haleon by 293.7% in the third quarter. Atlantic Union Bankshares Corp now owns 3,697 shares of the company’s stock worth $33,000 after buying an additional 2,758 shares during the period. Geneos Wealth Management Inc. raised its holdings in Haleon by 33.0% during the 1st quarter. Geneos Wealth Management Inc. now owns 4,846 shares of the company’s stock valued at $50,000 after buying an additional 1,203 shares during the last quarter. Finally, Mather Group LLC. bought a new stake in Haleon during the 3rd quarter valued at $52,000. 6.67% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the stock. Deutsche Bank Aktiengesellschaft lowered shares of Haleon from a “hold” rating to a “sell” rating in a report on Monday, January 12th. HSBC upgraded shares of Haleon from a “hold” rating to a “strong-buy” rating in a report on Wednesday, January 21st. Morgan Stanley restated an “overweight” rating on shares of Haleon in a report on Monday, December 15th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Haleon in a research report on Thursday, January 22nd. Finally, Jefferies Financial Group reiterated a “buy” rating on shares of Haleon in a report on Tuesday, January 20th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $12.33.

Haleon Trading Up 0.1%

Shares of NYSE:HLN traded up $0.02 on Friday, hitting $10.09. The company had a trading volume of 4,002,894 shares, compared to its average volume of 8,386,034. The firm’s 50-day simple moving average is $10.50 and its two-hundred day simple moving average is $9.85. The firm has a market capitalization of $44.91 billion, a price-to-earnings ratio of 25.89 and a beta of 0.18. The company has a quick ratio of 0.71, a current ratio of 0.92 and a debt-to-equity ratio of 0.47. Haleon PLC Sponsored ADR has a 1 year low of $8.71 and a 1 year high of $11.42.

Haleon Dividend Announcement

The business also recently disclosed a dividend, which will be paid on Thursday, May 14th. Shareholders of record on Friday, April 10th will be issued a $0.1307 dividend. The ex-dividend date is Friday, April 10th. This represents a yield of 251.0%. Haleon’s dividend payout ratio (DPR) is 28.21%.

About Haleon

Haleon plc (NYSE:HLN) is a global consumer healthcare company formed through the separation of a large pharmaceutical group’s consumer health business in 2022. Headquartered in the United Kingdom, Haleon develops, manufactures and markets a broad portfolio of over‑the‑counter medicines, oral health products, vitamins, minerals and supplements, and other consumer health goods designed for daily self‑care and symptom relief.

The company’s product mix spans categories such as oral care (toothpastes and sensitivity treatments), pain relief and analgesics, respiratory remedies, digestive health products, topical treatments and nutritional supplements.